Physician profile
Jonathan Ticku
NPI 1922259589
$2,989.17
in general payments reported to CMS, 2019-2025
8 companies · $71.55 in 2025
The $71.55 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $64.99 · 2021: $1,362 · 2022: $631 · 2023: $250 · 2024: $610 · 2025: $71.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $525 · Food and Beverage: $316 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $525.00 |
| Food and Beverage | $316.02 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $1,200.00 | 2021 | |
| Beigene USA, INC. | $525.00 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $525.00 | 2024 | Lynparza |
| Janssen Biotech, INC. | $385.15 | 2020-2023 | Erleada |
| Janssen Scientific Affairs, LLC | $156.35 | 2024-2025 | Erleada, Tecvayli, Talvey |
| Alexion Pharmaceuticals, INC. | $150.00 | 2021 | |
| Genentech USA, INC. | $35.75 | 2023 | Columvi, Polivy |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Ticku listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.